All In MedTech

Device Trial Radar · NCT04539964

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 243 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

243

Actual

Start

Jan 11, 2021

Primary completion

May 16, 2024

Study completion Oct 2027

Sponsor

Lead sponsor
SetPoint Medical CorporationNot on our public-company list
Sponsor type
Industry
First posted
Sep 7, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Implant ProcedureProcedure

    The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

  • Conventional Synthetic DMARDDrug

    All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

  • Active stimulationDevice

    Active stimulation for 1 min once per day

  • Non-active stimulationDevice

    Non-active stimulation for 1 min once per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the American College of Rheumatology (ACR) 20 ResponseTime frame: Week 12

Locations

43 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Arthritis ans Rheumatology Research, PPLC

    Mesa, Arizona

  • Arizona Arthritis Rheumatology & Research, PLLC

    Phoenix, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC

    Tucson, Arizona

40 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.